Article Details
Retrieved on: 2024-04-13 13:30:58
Tags for this article:
Click the tags to see associated articles and topics
Summary
This biotech-focused article details an immunological study using engineered TCR-T cells and the effects on tumor cells in immunodeficient mice, involving biotechnological companies like GemPharmatech and BioLegend, with a strong emphasis on immunotherapy and cellular engineering in the United States and China.
Article found on: www.nature.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here